- Home
- FNWB vs COEP Comparison
FNWB vs COEP Comparison
Compare FNWB & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FNWB | COEP |
|---|---|---|
| Founded | 1923 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.9M | 100.4M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | FNWB | COEP |
|---|---|---|
| Price | $9.97 | $15.15 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $13.50 | N/A |
| AVG Volume (30 Days) | 31.1K | ★ 91.6K |
| Earning Date | 01-28-2026 | 11-14-2025 |
| Dividend Yield | ★ 1.41% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $54,052,000.00 | $500,996.00 |
| Revenue This Year | $31.86 | N/A |
| Revenue Next Year | $10.64 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.47 | N/A |
| 52 Week Low | $6.05 | $2.31 |
| 52 Week High | $12.10 | $21.41 |
Technical Indicators
Market Signals| Indicator | FNWB | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 65.70 | 43.61 |
| Support Level | $9.80 | $14.82 |
| Resistance Level | $10.14 | $16.60 |
| Average True Range (ATR) | 0.20 | 1.43 |
| MACD | -0.04 | -0.24 |
| Stochastic Oscillator | 51.92 | 1.18 |
Price Performance
Historical ComparisonAbout FNWB First Northwest Bancorp
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It includes deposit and lending transactions that are supplemented with other borrowing and investing activities. The bank's principal lending activities are focused on first lien one- to four-family mortgage loans, commercial and multi-family real estate loans, construction and land loans, commercial business loans, and consumer loans.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.